GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Agile Therapeutics Inc (STU:0AL) » Definitions » ROC (Joel Greenblatt) %

Agile Therapeutics (STU:0AL) ROC (Joel Greenblatt) % : -3,064.39% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Agile Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Agile Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3,064.39%.

The historical rank and industry rank for Agile Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

STU:0AL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1919.94   Med: -259.66   Max: -132.26
Current: -1913.76

During the past 12 years, Agile Therapeutics's highest ROC (Joel Greenblatt) % was -132.26%. The lowest was -1919.94%. And the median was -259.66%.

STU:0AL's ROC (Joel Greenblatt) % is ranked worse than
96.05% of 1064 companies
in the Drug Manufacturers industry
Industry Median: 7.805 vs STU:0AL: -1913.76

Agile Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -61.00% per year.


Agile Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Agile Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agile Therapeutics ROC (Joel Greenblatt) % Chart

Agile Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -133.80 -325.72 -502.03 -401.42 -1,883.94

Agile Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,470.45 -2,403.09 -1,867.26 -290.60 -3,064.39

Competitive Comparison of Agile Therapeutics's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agile Therapeutics's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Agile Therapeutics's ROC (Joel Greenblatt) % falls into.



Agile Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.299 + 2.259 + 1.18) - (11.709 + 0 + 2.549)
=-7.52

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.11 + 2.511 + 0.773) - (16.39 + 0 + 0.763)
=-10.759

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Agile Therapeutics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-15.276/( ( (0.55 + max(-7.52, 0)) + (0.447 + max(-10.759, 0)) )/ 2 )
=-15.276/( ( 0.55 + 0.447 )/ 2 )
=-15.276/0.4985
=-3,064.39 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agile Therapeutics  (STU:0AL) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Agile Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Agile Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Agile Therapeutics (STU:0AL) Business Description

Traded in Other Exchanges
Address
500 College Road East, Suite 310, Princeton, NJ, USA, 08540
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.

Agile Therapeutics (STU:0AL) Headlines

No Headlines